arrow
S

Saadettin Kılıçkap

istinye university
H指数:31
被引数:4,949

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

晚期胸腺癌二线治疗的实际疗效:一项多中心土耳其肿瘤学组(TOG)研究

2026-08-270
OA
Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician–patient survey

在土耳其BRCA阳性个体中对植入前遗传学检测(PGT-M)的认知:一项医患双重调查

2026-07-070
OA
Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients

比较固定剂量与体重基础剂量纳武利尤单抗治疗非小细胞肺癌患者的疗效

2026-05-080
OAAI
Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab

基线维生素D状态及接受纳武利尤单抗治疗的晚期非小细胞肺癌患者的临床结局

2026-04-140
OAAI
Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

转移性髓样甲状腺癌中的酪氨酸激酶抑制剂治疗:土耳其肿瘤学组的真实世界数据

2026-03-190
OA
The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer

接受免疫疗法治疗的晚期肺癌患者中,早期肺部免疫预后指数变化的预后意义

2026-02-210
OAAI
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

brigatinib 在晚期ALK阳性NSCLC中的真实世界有效性与安全性:土耳其肿瘤学组进行的一项全国多中心研究

2026-02-110
PRE
Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group (TOG)

葡萄膜黑色素瘤的真实治疗模式和生存率: 土耳其肿瘤学组 (TOG) 的一项多中心队列研究

Cancers
IF4.4
2026-01-280
OA
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

与健康相关的生活质量和免疫检查点抑制剂治疗长期存活者的心理社会结局:一项全国性多中心研究

2025-12-100
OA
Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study

局部晚期直肠癌患者新辅助化放疗后达到病理完全缓解的长期肿瘤学结局:土耳其肿瘤学组研究

2025-12-010
PRE
Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study(vol61 , 638 , 2025)

免疫疗法与化疗在晚期胸膜间皮瘤中的疗效比较:一项土耳其肿瘤学小组(TOG)研究(vol61,638,2025)

2025-11-070
OAAI
Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG)

帕博西利在脂肪肉瘤中的应用:土耳其肿瘤学组(TOG)的真实世界多中心数据

2025-09-010
PRE
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1

Cemiplimab单药治疗PD-L1表达≥50%的晚期NSCLC患者的一线治疗:EMPOWER-Lung 1研究五年结局

2025-03-190
OAAI
Integrating machine learning prediction and causal inference analysis to unravel determinants of progression in EGFR-mutant, advanced NSCLC

整合机器学习预测与因果推断分析,以揭示EGFR突变、晚期非小细胞肺癌进展的决定因素

2024-09-011
PRE
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
2024-09-013
OA
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

Entrectinib治疗ROS1-positive晚期非小细胞肺癌: 2/3期BFAST试验

2024-06-192
OAAI
The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma

辅助PD-1抑制剂在手术切除的III/IV期肢端黑色素瘤患者中的有效性

2024-03-112
OAAI